BeijngFH Health Cohort Study
Recruiting · NCT05546086 · Observational (researchers observe without assigning treatment) · Lead sponsor: Beijing Friendship Hospital
View the official record on ClinicalTrials.gov →What this trial is about
Metabolic associated fatty liver disease(MEFLD) is a major chronic liver disease that can lead to various adverse events, such as liver cancer, cardiovascular disease, and chronic kidney disease. The present community-based cohort study enrolls subjects who take health physical examinations at the sub-center outpatient department, Beijing Friendship Hospital. Investigators collect their baseline information, including demographic data, clinical history, physical examination, laboratory results, imageological examination, and so on. Follow-up surveys are conducted annually and the information collected is the same as the baseline. The outcome information, including cardiovascular disease, malignancy, liver cirrhosis, liver decompensation, liver transplantation, and all-cause mortality, are obtained by linking to the hospital discharge database and death registration system of Beijing. The primary aim of the study is to build a risk-stratified evaluation system for MAFLD through the cohort.
Who can take part
Inclusion criteria
- Aged 18 years or older
- Permanent residents in Beijing
- Signing informed consent
Where it is running
1 location listed.
- Beijing Friendship Hospital, Capital Medical University - Beijing, China